Parkinson's Disease Tulip


advertisement
 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 04-15-2008, 09:48 AM #1
imark3000 imark3000 is offline
Member
 
Join Date: Nov 2007
Location: Calgary-Canada
Posts: 821
15 yr Member
imark3000 imark3000 is offline
Member
 
Join Date: Nov 2007
Location: Calgary-Canada
Posts: 821
15 yr Member
Default $5.6-Million Award for Trial of Inosine

Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
http://www.earthtimes.org/articles/s...s,351176.shtml
NEW YORK, April 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced a $5.6-million award to drive a Phase 2 clinical trial to investigate the potential of inosine -- a naturally occurring chemical that gives rise to urate in the body -- to slow or stop the progression of Parkinson's disease.
The work is being funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) 2007 initiative. LEAPS 2007 was funded with a lead gift from the Edmond J. Safra Foundation, one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.
Urate is a natural metabolite and major antioxidant in humans. Previous studies found that healthy people with higher urate levels in the blood had a reduced risk of developing PD. More recent work, including a study published today in the journal Archives of Neurology authored by two of the principal investigators on this LEAPS award, have linked higher urate levels to a possible slower progression of the disease.
The goals of this LEAPS award are to determine the safety of using inosine to raise urate levels, and to assess optimal dosage for therapeutic effect. Ninety people recently diagnosed with Parkinson's disease will be enrolled in a randomized, double-blind clinical trial to determine whether and at what dose inosine can safely elevate levels of urate in cerebrospinal fluid. Three months after enrollment, cerebrospinal fluid will be tested for urate levels. If a tolerable dose of inosine adequately increases urate in the cerebrospinal fluid, subjects will continue on treatment for up to two years to assess long-term safety.
"This project is precisely the sort of work that The Michael J. Fox Foundation exists to identify and drive forward for patients' benefit," said Katie Hood, the Foundation's CEO. "The study is based on interesting epidemiological observations, but because inosine is a publicly available compound, no corporate entity has the financial incentive to fund clinical research to definitively assess its potential. We believe it is our obligation to the PD community to step in where other funders may be unwilling to go, and ensure that innovative approaches like this one do not stall for lack of resources."
Inosine is widely available to consumers in dietary supplement form. The researchers emphasize that people with Parkinson's should not take inosine except in the context of a closely monitored clinical trial in which potential benefits and risks are carefully balanced. The evidence to date surrounding inosine and PD does not prove a cause-effect relationship. Additionally, elevated urate levels are known to carry certain health risks, only some of which have been definitively characterized to date. Kidney stones and gout are known risks; cardiovascular disease is a possible risk. (In the clinical trial, safety measures will be in place to help avoid these conditions, and to detect and treat them should they arise.)
__________________
Imad
Born in 1943. Diagnosed with PD in 2006.
imark3000 is offline   Reply With QuoteReply With Quote
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
notice of award lady bug Social Security Disability 1 09-02-2007 08:33 PM
Falconer Man Receives Award BobbyB ALS News & Research 0 06-18-2007 07:24 AM
CLINICAL TRIAL...Phase III Trial with Pimavanserin in Patients with PD Psychosis Stitcher Parkinson's Disease Clinical Trials 0 06-16-2007 12:23 AM
Murray Charters Advocacy Award...Louis Fishman Acvocacy Award Stitcher Parkinson's Disease 1 02-12-2007 01:50 PM


All times are GMT -5. The time now is 06:15 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.